- Saturday, 13 June 2015
- AstraZeneca announces Phase III results for lesinurad in combination with febuxostat in tophaceous gout patients at European League Against Rheumatism Annual Congress (EULAR 2015) AstraZeneca today presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated that lesinurad in combination with febuxostat lowered serum uric acid (sUA) levels and reduced tophus area to a greater extent than febuxostat alone. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA. Lesinurad works in combination with febuxostat to provide a dual mechanism of action which increases excretion and decreases production of uric acid.
- Tuesday, 2 June 2015
- AstraZeneca updates on immuno-oncology combinations development program at ASCO 2015 AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 1, 2015.
- Sunday, 31 May 2015
- AstraZeneca presents positive data on AZD9291 in first-line EGFR mutated lung cancer at ASCO 2015 AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC). Data showed that 81% (95% confidence interval (CI) 68% to 89%) of patients on a once daily dose of AZD9291 were progression free at 9 months; overall response rate was 73% (95% CI 60% to 84%). The longest duration of response was ongoing at 13.8 months at the time of data cutoff.
- Saturday, 30 May 2015
- AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015 AstraZeneca and MedImmune, AstraZeneca’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
- Wednesday, 20 May 2015
- Olympic gold medalist Jackie Joyner-Kersee teams up with AstraZeneca to raise awareness about opioid-induced constipation AstraZeneca and Daiichi Sankyo, Inc. today announced that they have partnered with six-time Olympic medalist Jackie Joyner-Kersee to increase awareness of opioid-induced constipation (OIC).
- Saturday, 16 May 2015
- MOVANTIK™ (naloxegol) safety analyses of opioid-induced constipation patients 65 and older with chronic non-cancer pain Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies presented today at Digestive Disease Week (DDW) 2015 in Washington, D.C. showed that MOVANTIK™ (naloxegol) had a similar incidence of adverse events (AEs) among elderly patients as compared to placebo or usual care. The study evaluated the effects of daily oral administration of MOVANTIK 12.5 mg or 25 mg vs placebo among outpatients 65 years and older with opioid-induced constipation (OIC) and chronic non-cancer pain.
- Wednesday, 13 May 2015
- AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at ASCO 2015 AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2015. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
- Wednesday, 29 April 2015
- US FDA grants priority review for potential new indication for BRILINTA AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrollment. The Prescription Drug User Fee Act goal date will be in the third quarter of 2015.
- Monday, 27 April 2015
- New initiative to get heart, stroke treatment guidelines to patients faster The American Heart Association is a leader in developing science-based treatment guidelines known to improve outcomes for heart disease and stroke patients. But getting those guidelines consistently used in patient care can often take years. That’s why the association is launching a new initiative that will not only speed up the process for developing guidelines, but also help doctors know about and use them sooner and more often.
- Friday, 24 April 2015
- AstraZeneca PLC first quarter results 2015 Visit our global site to view full details of the event.
These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.
View information on AstraZeneca products, including their current US Prescribing Information.